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Abstract
Background
There are limited data on the performance of the use of fixed-dose combination (FDC) TB
drugs when used under programmatic settings in high TB-endemic countries. We evaluated
the efficacy and safety of FDC versus loose formulation (LF) TB treatment regimens for
treatment of pulmonary TB (PTB) in the context of actual medical practice in prevailing con-
ditions within programmatic settings in five sites in two high TB-burden African countries.
Methods
A two-arm, single-blind, randomized clinical trial comparing FDCs with separate LFs involv-
ing 1000 adults newly diagnosed with culture positive PTB was conducted at five sites in
two African countries between 2007 and 2011. Participants were randomized to receive
daily treatment with anti-TB drugs given as either FDC or separate LFs for 24 weeks
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(intensive phase– 8 weeks of isoniazid, rifampicin, ethambutol and pyrazinamide; continua-
tion phase– 16 weeks of rifampicin and isoniazid). Primary outcome measures were micro-
biological cure and safety at the end of six months’ treatment; pre-specified non-inferiority
margin for difference in cure rate was 4%. The primary efficacy analysis was based on the
modified intent to treat (mITT) cohort comprising all randomized patients with a positive
baseline culture result for TB and who received at least one dose of study treatment.
Patients missing end of treatment culture results were considered failures. Further analyses
were done in which mITT patients without an end of treatment (EOT) culture were excluded
in a complete case analysis (mITTcc) and a per protocol cohort analysis defined as mITTcc
patients who received at least 95% of their intended doses and had an EOT culture result.
Results
In the mITT analysis, the cure rate in the FDC group was 86.7% (398/459) and in the LF
group 85.2% (396/465) (difference 1.5-% (90% confidence interval (CI) (-2.2%– 5.3%)). Per
Protocol analysis showed similar results: FDC 98.9% (359/363) versus LF 96.9% (345/
356), (difference 2.0% (90% CI: 0.1%– 3.8%)). The two arms showed no significant differ-
ences in terms of safety, early culture conversion and patient adherence to treatment.
Interpretation
The comparison of the two drug regimens satisfied the pre-specified non-inferiority criterion.
Our results support the WHO recommendations for the use of FDC in the context of actual




Tuberculosis (TB) remains a major global public health problem [1]. Patient non-adherence to
TB treatment regimens and inappropriate prescription of TB drugs are important contributing
factors to treatment failure and development of drug resistant strains ofMycobacterium tuber-
culosis [2] which now threaten gains being made in global TB control [3]. The World Health
Organization (WHO) and the International Union Against Tuberculosis and Lung Disease
(IUATLD/The Union) endorsed the use of Fixed Dose Combination (FDC) drug formulations
for treatment of pulmonary TB (PTB) in 1994 [4]. These recommendations were based mainly
on expert opinion without any evidence base from randomized clinical trials or systematic
evaluation of safety and efficacy at programme level. The underlying assumption was that FDC
formulations would improve prescribing, make dispensing easier, simplify TB drug treatment,
enable patient acceptability, reduce risk of inappropriate dosing and pill burden, and prevent
inadvertent monotherapy arising from physician or patient error [5]. Over the past 2 decades
national TB control programmes of most African countries have introduced FDCs for treat-
ment of TB [4,6].
In 1997, concerns about the bioavailability of rifampicin (because of its relatively poor bio-
availability when combined with isoniazid) led WHO and the IUATLD to issue further
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guidelines for ensuring the bioavailability of each drug component of the FDC formulations
[7]. Subsequently several clinical trials and observational studies have assessed the effectiveness
of FDC in reducing treatment failure, improving patient compliance, disease relapse and emer-
gence of drug resistance. A recent systematic review and meta-analysis of 15 trials [8] showed
no benefit to treatment outcomes. Despite conflicting results, the FDC formulations continue
to be recommended by WHO [9], the American Thoracic Society [10] and International Stan-
dards for Tuberculosis Care [11]. Furthermore, clinical trials conducted under optimal
research conditions do not reflect the actual performance of test regimens under conditions of
routine programmatic clinical practice. There are scant data on the performance of FDCs in
terms of safety and efficacy when used under prevailing health services conditions in sub-Saha-
ran African countries. We thus performed a randomized clinical trial to evaluate the efficacy
and safety of FDC versus loose formulation (LF) TB treatment regimens for treatment of pul-
monary TB (PTB) in the context of actual medical practice in prevailing conditions within pro-
grammatic settings in five sites in two high TB/HIV burden African countries.
Methods
Study design and participants
This study was a multi-centre, two-arm, single-blind randomized trial which evaluated the
non-inferiority of FDC (test arm) to LF (control arm) TB drugs in newly diagnosed patients
with PTB. The drug regimens for this study consisted of 8 weeks of daily, directly observed
treatment (DOT) for the intensive phase, followed by 16 weeks of daily DOT (continuation
phase) as per national TB programme guidelines.
Ethical considerations: The study received approval from the AHRI/ALERT and National
Ethical Review committees and the Drug Administration and Control Authority (DACA) in
Ethiopia; the University of Nigeria Teaching Hospital, Health Research Ethics Committee in
Nigeria; and the WHO Research Ethics Review Committee.
Eligibility criteria
Inclusion criteria were: adults (>18 years) with newly diagnosed, sputum smear acid-fast
bacilli positive, PTB; weight of at least 40kg; a verifiable home address; willingness to have an
HIV test; CD4 counts>350cells/mm3 if HIV positive; and written informed consent. Exclusion
criteria were: HIV-positive patients on antiretroviral treatment; previous history of TB treat-
ment; co-morbidities requiring hospitalization; concomitant immunosuppressive treatment;
psychiatric illness, alcohol or drug abuse; pregnancy, and extrapulmonary-TB.
Study sites
The study was conducted in five sites in the two African countries: Ethiopia–(i) St. Peter’s Hos-
pital, (ii) Bole Health Centre, and (iii) Adama Hospital; Nigeria–(iv) Mile 4 Hospital, and (v)
Aba South Health Centre. These two countries were selected following a WHO/TDR-spon-
sored workshop to develop research capacity of national TB control programmes in limited
resource settings. The process entailed a competitive approach that identified the most appro-
priate countries to design and implement the identified research questions. The protocol design
was approved by WHO, prior to selection of countries to conduct the clinical study. The trial
was coordinated by the Armauer Hansen Research Institute (AHRI) jointly with the Ministry
of Health, Ethiopia and German Leprosy and Tuberculosis Relief Association (GLRA), in con-
junction with the Ministry of Health, Nigeria and conducted in January 2007 to April 2011.
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Procedures
2,209 TB suspected patients were screened for pulmonary TB by sputum smear Ziehl-Neelsen
stain or fluorescence microscopy. Patients were considered positive for pulmonary TB if they
had 2 out of 3 smears positive or 2 out of 5 smear positive in the event that only one of the first
three smears was positive. Patients with newly diagnosed PTB were counselled appropriately to
ascertain their willingness to participate in the trial and were provided information sheet with
written informed consent. If illiterate an independent witness was chosen by individual patient
to read the written materials. The next step was to apply inclusion and exclusion criteria,
including physical examination and laboratory tests (liver function test, HIV counselling and
testing, fasting blood sugar test, full blood count, uric acid, renal function test and urinary preg-
nancy test for women in reproductive age). At all levels patients were excluded if they did not
meet the inclusion criteria. Subsequently, 1,209 enrolled patients were randomly assigned into
two arms to receive either LF (control arm) or FDC (test arm) for a total of 24 weeks: intensive
phase–8 weeks [56 doses] of daily isoniazid, rifampicin, ethambutol and pyrazinamide; contin-
uation phase: 16 weeks [112 doses] of daily rifampicin and isoniazid. The four FDCs and the
two FDCs used were identical across the different study sites and both formulations included
rifampicin. The first dose of drugs for each patient was based on the pre-treatment weight; sub-
sequent doses were based on the weight at each follow-up visit. The anti-TB drug preparations
were all from the same source (Lupin Pharmaceuticals, India—a WHO-approved pre-qualified
source and supplier of TB drugs to the Nigerian and Ethiopian national TB programmes
through Global Drug Facility). The names, dose preparations, indications and duration of use
of the medications were properly documented.
Bacteriology
At each visit, two sputum samples were collected and examined for the presence of acid-fast
bacilli, either by Ziehl-Neelsen stain or by fluorescence microscopy. Patients were considered
positive if they met the following national programme criteria: (i) two out of three consecutive
sputum smears are read as positive, or (ii) two out of five are read as positive in the event that
only one of the first three smears is positive (in which case the patient will be asked for two
more specimens: one morning, one spot). All smears were also cultured on LJ slopes in accor-
dance with WHO guidelines. The proportion method was used to test for susceptibility to the
TB drugs used in this study.
Outcome measures
Primary outcome measure was cure at end of 24 weeks treatment (6 months short-course che-
motherapy). If week 24 results were unavailable, week 20 was used. Cure was defined as one
negative sputum culture in patients who did not fail treatment.
Secondary outcome measures were: a) early response rates (proportion of patients with nega-
tive culture results at 8 weeks after initiation of therapy); b) proportion of patients with recur-
rence during the 72 weeks follow up period after the end of treatment; c) proportion cured in
HIV positive patients; d) proportion of patients with serious adverse events any time during
chemotherapy; e) proportion of patients with any adverse events during chemotherapy; and f)
proportion of patients completing treatment.
Sample size
Sample size for this study was calculated to demonstrate FDCs' non-inferiority to the LF in
terms of efficacy in the treatment of TB. To this effect, 498 patients per arm was sufficient to
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rule out a clinically acceptable 4% decrease in the proportion of patients cured on FDC with
90% power using a one-sided, 5% level Miettinen and Nurminen score test assuming a 96%
cure rate in the LF arm and no more than 10% of patients without an EOT culture (who would
be excluded from analysis). Thus, 500 participants were randomized to each arm.
Given concerns that a complete case analysis could be biased, the primary analysis was
changed such that patients without an EOT culture would be counted as failures. If 10% of
patients had missing EOT culture, the cure rate in the LF arm would drop to 86% and study
power would decrease to 57%. However, if 5% of patients had missing culture, the LF cure rate
would be 91% and power would be about 70%.
Randomization and masking
Participants were allocated to treatment arms according to a computer-generated randomiza-
tion list prepared and held by WHO/TDR, the study sponsor. Each centre was provided with a
batch of sealed opaque envelopes. These were opened, and drugs dispensed to participants,
only by a treatment nurse who was not an investigator in the trial. The treatment nurses kept
treatment allocation logs which were not available to the investigators until conclusion of the
analysis.
Statistical analysis
The efficacy analysis used data from the modified intent to treat (mITT) cohort which con-
sisted of all randomised patients who had a positive sputum culture result at baseline and who
had taken at least one dose of study treatment. Those mITT patients who had an unknown
sputum culture result at end of treatment (EOT) were assumed to be failures. This efficacy
analysis is denoted by mITT.
The number of participants cured at week 24 was tabulated for each trial arm and expressed
as percentages. The difference between study groups was tested using the Agresti-Caffo method
[12] to calculate a lower limit one-sided 95% confidence interval (or its equivalent—the lower
limit of a two-sided 90% CI). The FDC arm was considered non-inferior to the LF if the lower
limit of the CI for the risk difference (% FDC cured–%LF cured) did not extend below -4%.
Two further analyses were performed. The first used the per protocol cohort (PP), a subset
of the mITT patients who had completed treatment and had a known sputum culture result at
end of treatment. Treatment adherence was defined as those who took at least 54/56 (96.4%)
doses in the intensive phase and at least 107/112 (95.5%) doses in the continuation phase. The
second analysis was a complete case scenario where mITT patients who had an unknown spu-
tum culture result at end of treatment (EOT) were excluded. These efficacy analyses are
referred to as PP and mITTcc.
Seven secondary outcomes were analysed and treatment arms compared: (i) conversion at
week 8 (early response) using two cohorts (mITT and PP), (ii) treatment completion using ITT
cohort, (iii) cure among HIV+ patients using ITT cohort, (iv) occurrence of any drug related
adverse events stratified by treatment phase and overall using ITT cohort, (v) occurrence of
any serious adverse event stratified by treatment phase and overall using ITT cohort, (vi)
occurrence of death stratified by treatment phase and over all using ITT cohort and (vii)
relapse among those cured at week 24. For each of these outcomes, difference in the proportion
of the occurrence of the target event between the treatment FDC arm and LF arm were calcu-
lated. Pearson’s chi-square test with continuity correction was used to assess the statistical sig-
nificance. The exception was relapse for which the finding was described in the narrative.
Efficacy and Safety of 4FDC for TB Treatment
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Data access and guarantee
Joseph N. Chukwu and Abraham Aseffa had full access to all the data in the study. Abraham
Aseffa had final responsibility for the decision to submit for publication.
Results
The study enrolled and randomized a total of 1000 patients (500 in FDC arm; 500 in LF arm)
between 2007 and 2010, and completed follow-up in 2011 (Fig 1). The mITT analysis included
924 participants (FDC arm: 459/500 [91.8%]; LF arm: 465/500 [93.0%]). Excluded participants
included 76 who had positive culture result at baseline (41 in FDC arm and 35 in the LF arm).
Fig 1. Flow Chart showing recruitment and follow-up during treatment period.
doi:10.1371/journal.pone.0157434.g001
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The per protocol (PP) cohort was a subset of the mITT and excluded a further 162 participants
with inadequate treatment (75 FDC and 87 LF), plus 43 patients who completed treatment but
without a known EOT culture result (21 FDC and 22 LF). Thus, the PP analysis was based on
719 patients (FDC arm: 363/459 [79.1%]; LF arm: 356/465 [76.6%]).
Baseline characteristics of mITT study participants were similar in the two groups (Table 1).
The majority of study participants (79.3%) were less than 40 years of age; 57.4% were males,
17.1% had noticeable symptoms of TB for more than 24 weeks, only 5.4% were HIV positive,
and 1.4% had concurrent diseases.
Treatment adherence
Treatment adherence was defined as at least 54/56 (96.4%) doses taken in the 8 week intensive
phase and at least 107/112 (95.5%) doses taken in the 16 week continuation phase. Among the
total randomised population (ITT), compliance was very high. In the intensive phase 96.6%
(966/1000) completed treatment; 97.0% (485/500) in the FDC arm and 96.2% (481/500) in the
LF arm (p = 0.6). Similarly, 80.7% (807/1000) of the total study participants completed treat-
ment in the continuation phase (FDC: 81.6% (408/500) vs LF:79.8% (399/500), p = 0.5). Of the
mITT cohort, 82.5% (762/924) completed treatment, 83.7% (384/459) in the FDC arm and
81.3% (378/465) in the LF arm (p = 0.3).
Efficacy analysis and early response
Results of efficacy analysis using mITT cohort and PP cohort are summarized in Table 2 and
Fig 2. Of the FDC group, 398 participants and 396 in the LF group were culture negative at
end of treatment which resulted in a cure (favourable result) of 86.7% (398/459) in FDC
group and 85.2% (396/465) in LF group (difference: 1.5%; 90% CI: -2.2-% to 5.3-%). The
non-statistical significance of the difference in the proportion of patients cured was also
maintained when the analysis was repeated in the PP cohort. In the FDC group, 98.9% (359/
363) had a favourable outcome versus 96.9% (345/356) in the LF group (difference 2.0%; 90%
CI: 0.1 to 3.8). In the second analysis using the complete case scenario, 98.8% (398/403) in
the FDC compared to 97.1% (396/408) in the LF group had a favourable outcome (difference
of 1.7%: 90% CI: 0.0% to 3.4%). This difference also falls within the pre-specified margin of
non-inferiority.
The FDC arm had 20 HIV+ study participants, 16 of whom (80.0%) were cured of TB. Simi-
larly, 24 (80.0%) of 30 HIV+ study participants in the LF arm were cured of TB. However, the
observed difference, was not statistically significant (90% CI: -19.0% to 19.0%).
Early conversion rates in the mITT cohort were 79.5% (365/459) for the FDC group and
77.9% (362/465) for the LF group. In the PP cohort among those with month 2 culture results,
early conversion rates were similar: 85.6% (303/354) in the FDC group and 83.0% (293/353) in
the LF group.
Recurrence
Based on the programmatic definition of recurrence utilizing microscopy, there were two and
eleven cases of recurrence, respectively, in the FDC and LF arms in one of the 36, 48, 72 or 96
week follow-ups. Only one of these cases in the LF arm was smear positive at two time points
(i.e., week 36 and week 48) and that particular patient was confirmed culture positive at week
48.
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Safety analysis
Results from safety analysis are summarized in Table 3. In both treatment arms, the occurrence
of drug related adverse events as well as serious adverse events were more frequent during the
intensive phase compared to the continuation phase. However, there was no significant
Table 1. Baseline Characteristics of mITT Population.
Treatment arm
FDC Arm LF ARM Total
No. % No. % No. %
Study country
Ethiopia 239 52 242 52 481 52
Nigeria 220 48 223 48 443 48
Age (yr)
<25 173 38 172 37 345 37
25-39 185 40 203 44 388 42
> = 40 101 22 90 19 191 21
Sex
Female 188 41 206 44 394 43
Male 271 59 259 56 530 57
Weight (Kg)
40–45 130 28 129 28 259 28
46–55 281 61 280 60 561 61
56–66 39 8 51 11 90 10
67+ 9 2 5 1 14 2
BMI (kg/m2)
Underweight <18.5 299 65 292 63 591 64
Overweight (26.0–29.9) 2 0 0 0 2 0
Obese (> = 30.0) 0 1 0 1 0 0
Healthy(18.5–25.9) 158 34 172 37 330 36
Duration of TB symptoms
<3 weeks 10 2 13 3 23 2
-6 wks 64 14 63 14 127 14
7–12 wks 183 40 183 39 366 40
12–24 wks 136 30 114 25 250 27
>24 wks 66 14 92 20 158 17
Haemoglobin (g/dL)
<8.0 2 0 8 2 10 1
> = 8.0 457 100 457 98 914 99
HIV test
Positive 20 4 30 6 50 5
Negative 438 95 435 94 873 94
Not available 1 0 0 0 1 0
CD4 Count
<350 4 20 6 20 10 20
> = 350 16 80 24 80 40 80
Concurrent disease at baseline
Yes 7 2 6 1 13 1
No 452 98 459 99 911 99
doi:10.1371/journal.pone.0157434.t001
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difference in patient safety between the two treatment arms during intensive as well as continu-
ation phases. Similarly, during the whole period of chemotherapy the occurrence of drug
related adverse events (difference in proportion: -0.8%; 90% CI: -4.5%– 2.9%), serious adverse
events (difference in proportion = -1.4%; 90% CI: -3.6%– 0.8%) or mortality (difference in pro-
portion = -0.1%; 90% CI: -1.6%– 1.2%) was similar in both groups.
Table 2. mITT and Per protocol analysis at end of treatment.
4FDC arm LF arm
mITT Cohort N % N % Difference (90%CI)
Unfavourable Result 61 13.3% 69 14.8%
Favourable Result (cure) 398 86.7% 396 85.2% 1.55% (-2.22; 5.32)
Total 459 100.0% 465 100%
4FDC arm LF arm
Per Protocol Cohort N % N % Difference (90%CI)
Unfavourable Result 4 1.1% 11 3.1%
Favourable Result (cure) 359 98.9% 345 96.9% 2.0% (0.13; 3.8)
Total 363 100.0% 356 100.0%
doi:10.1371/journal.pone.0157434.t002
Fig 2. Evidence of Non Inferiority. The dotted lines indicate the margin on non-inferior for the difference
between the FDC and the LF region. Error bars represent the 90% confidence interval in the risk difference. In
Sensitivity 1 is a complete case analysis where all missing EOT culture results in the mITT cohort are
excluded. PP indicates per protocol.
doi:10.1371/journal.pone.0157434.g002
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Discussion
Our trial results provide additional important data on the use of FDCs compared to LFs, in the
context of actual medical practice in programmatic settings within health services in two high
TB/HIV-burden African countries—Nigeria and Ethiopia. There were five main findings: (i)
Non-inferiority in terms of efficacy in all three analyses (mITT, PP, and mITTcc), in two geo-
graphically distinct high TB/HIV endemic sub-Saharan African countries; (ii) Similar overall
efficacy at the end of short course chemotherapy for TB for both FDC and LF treatment arms;
(iii) Similar patient adherence to TB drug treatment for both FDC and LF; (iv) Similar drug-
related adverse events in both treatment arms; and (v) HIV infection did not impede the per-
formance of FDC and the safety profiles (even though numbers were small) were similar to
non-HIV infected TB patients.
Whilst our study is similar in design and objectives to published studies [13–15] it differs by
evaluating efficacy, safety and adherence to drug regimens during the entire 24-week treatment
period. In Study C [13] and in Blomberg and Fourie's study [16] the intervention FDCs, were
given only during the eight-week intensive phase of treatment. Comparing FDCs and LFs
throughout the course of treatment (6 months) enabled us to collect information on the contin-
uation phase of treatment—a crucial period when patients are likely to default. Furthermore,
our trial is the first to demonstrate non-inferiority in terms of efficacy in all three cohorts
(mITT, PP and mITTcc) between the two arms of the study, in two geographically distinct,
high TB/HIV endemic African countries.
Our study did not observe any significant difference in adverse events between the two
arms. This is consistent with findings from Study C and Blomberg and Fourie’s study [13,16]
confirming that the safety of anti-TB drugs was not dependent on fixed dose formulations
[13,17]. However, studies by Gravendeel et al. [18] and Su and Perng [19] found that patients
on the FDC regimen had adverse events less frequently than those on the LF.
There was no difference in DOT between hospital and health-care centres. Patients who
were admitted to hospital stayed only for the duration of the intensive phase (first 2 months),
solely for the purpose of DOT. Thereafter they were discharged to clinic DOT. Patient adher-
ence to FDCs and LFs was similar in both arms throughout the 24 weeks of treatment. Whilst
not statistically significant, we observed a trend indicating that LF recipients were more likely
to experience treatment failure. This suggests the possibility of improved performance with
Table 3. Comparison of safety of FDC and loose formulation of anti TB treatment during the intensive and continuation phases of TB treatment.
% (events/at risk)
Characteristic FDC Loose Difference
Serious adverse event
Intensive phase 1.2% (6/500) 2.3% (12/500) -1.2 (-2.8; 0.5)
Continuation phase 1.2% (6/483) 1.4% (7/478) -0.2 (-1.8; 1.3)
Over the course of treatment 2.4% (12/500) 3.8% (19/500) -1.4 (-3.6; 0.8)
Death
Intensive phase 0.6% (3/500) 0.8% (4/500) -0.2 (-1.4; 1.0)
Continuation phase 0.4% (2/483) 0.4% (2/278) -0.0 (-1.0; 1.0)
Over the course of treatment 1.0% (5/500) 1.2% (6/500) -0.1 (-1.6; 1.2)
Drug related adverse events
Intensive phase 6.9% (37/500) 7.4% (40/500) -0.5 (-3.6; 2.6)
Continuation phase 3.4% (17/483) 3.6% (18/478) -0.2 (-2.6; 2.1)
Over the course of treatment 10.6% (59/500) 13.3% (64/500) -0.8 (-4.5; 2.9)
doi:10.1371/journal.pone.0157434.t003
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FDCs although this observation appears contrary to adherence levels found in other studies
[8]. The reduction of pill burden may be an important factor in improved adherence and pre-
vention of the emergence of drug resistance when FDCs are used [17,20]. However, this has
not been demonstrated in this study and may require a larger study with a longer observational
period to elicit this effect, if present.
Previous studies have not been able to adequately document the performance of FDCs in
patients with TB/HIV co-infection treated within national programme settings [13, 21]. By
design, the high HIV co-infection rates in Ethiopia and Nigeria would have allowed our study
to evaluate the performance of FDCs among HIV-infected TB patients but the stringent eligi-
bility criteria precluded enrolment of sufficient numbers. HIV-infected TB patients within the
treatment thresholds of their national control programmes were excluded by the need to retain
a homogeneous cohort of comparable patients. The resultant small numbers of HIV-infected
TB patients prevented statistical comparison of any differences to HIV-uninfected TB patients.
The stringent enrolment criteria also may have impacted on the requisite number of
patients with TB drug relapse and treatment failure. This may have contributed to our inability
to evaluate the performance of FDCs in this category of patients. Analysis of the small numbers
of HIV-infected TB patients did not indicate any significant difference in the cure rate. The
HIV-infected TB study participants had CD4 counts above the antiretroviral treatment initia-
tion in both countries. Some studies have elicited an alteration in the absorption of anti-TB
drugs in cases of severe immune deficiency [22]. Further investigations involving a larger
cohort of HIV-infected TB patients are warranted and should ascertain the efficacy and safety
of FDCs in comparison to LFs; demonstrate any preferential adherence in favour of FDC or
LFs among HIV-infected TB patients; and the potential for an impact on recurrences, relapse
and treatment failure.
Our study had limitations which may have affected outcomes. The study subjects were
recruited from the routine TB programmes, due to study inclusion and exclusion criteria,
many patients with pulmonary TB who may have benefitted from the study were not enrolled
in the study. Subjects were not blinded to their treatment and this could be argued as a source
for potential bias due to increased safety awareness. However, the primary outcome measure
was bacteriology. This was performed by laboratory technicians blinded to the treatment allo-
cation and there was no difference in adherence between treatment arms, as also evidenced by
the non-significant differences in efficacy between treatment arms.
The findings of our study are of practical relevance for medical practice within national TB
programmes in Africa. Non-inferiority in efficacy and the non-significant difference in safety
profiles between FDC and LF provide a further scientific evidence base for validating WHO
recommendations for the use of FDCs by national TB programmes in high TB-endemic Afri-
can countries. FDC appears to be as effective and safe as LF and should continue to feature in
the treatment arsenal of national TB control programmes. An additional important aspect of
this study was the effective regional cooperation between national TB control programmes and
research institutions– ensuring programme relevance and optimal standards of study conduct
and capacity development.
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